Abstract
as the tyrphostin AG490 [6] , have been used to identify JAKs as responsible for constitutive signalling in primary cells from MPN patients [7] . But these inhibitors may target several other tyrosine kinases [8] .
Several [13] . 
MPL (TpoR) mutants

JAK1 mutants
The homologous JAK2 V617F mutations in JAK1 (V658F) and Tyk2 (V678F) also lead to constitutive activation [18] . Recently, it was shown that Ͼ20% of human T acute lymphoblastoid leukaemia harbour activating mutations in JAK1 [19] , including in the pseudokinase domain and the JAK1 V658F [20] . 
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